Proxy Votes Now

Home › Funds › MUTUAL FUND SERIES TRUST › AlphaCentric Life Sciences and Healthcare Fund

AlphaCentric Life Sciences and Healthcare Fund (LYFAX) proxy voting record 2025-2026

Fund family: MUTUAL FUND SERIES TRUST · Filed by MUTUAL FUND SERIES TRUST (CIK 1355064) · SEC series S000067055

Share classes and tickers: LYFAX (C000215731), LYFCX (C000215729), LYFIX (C000215730)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 477 with, 7 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 2 FOR, 5 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with MUTUAL FUND SERIES TRUST as a whole

The same two figures as MUTUAL FUND SERIES TRUST’s manager page (12,253 ballot items across 22 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsMUTUAL FUND SERIES TRUSTItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)82.6%43793.0%10,912
Backed environmental and social shareholder proposals at US companiesn/a117.7%334

Where this fund voted differently from most MUTUAL FUND SERIES TRUST funds

Each ballot item this fund voted is set against the votes of the other MUTUAL FUND SERIES TRUST funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most MUTUAL FUND SERIES TRUST funds on 2 items (10.5% of the 19 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost MUTUAL FUND SERIES TRUST fundsMgmtResult
Incyte Corporation2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerForAGAINST — 3 of 3 MUTUAL FUND SERIES TRUST fundsForElected, 80.9% support
Gilead Sciences, Inc.2026-04-30Shareholder To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.AgainstFOR — 2 of 3 MUTUAL FUND SERIES TRUST fundsForNot approved, 27.1% support

Download all 2 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 65.7% of this fund’s 484 such votes could be given a sector; the other 166 (34.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care31872.2%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2410
Audit-related580
Say-on-Pay470
Capital Structure450
Compensation390
Corporate Governance246
Other200
Extraordinary Transactions80
Shareholder Rights and Defenses30
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Gilead Sciences, Inc.April 30, 2026$3M153
Vertex Pharmaceuticals IncorporatedMay 13, 2026$3M151
Incyte CorporationJune 8, 2026$2M100
Neurocrine Biosciences, Inc.May 27, 2026$2M60
Oruka Therapeutics, Inc.June 2, 2026$1M40
Protagonist Therapeutics, Inc.June 17, 2026$1M50
Amgen Inc.May 19, 2026$1M151
Insmed IncorporatedMay 13, 2026$1M40

Notable votes against management

MeetingCompanyProposalFundMgmt
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
April 23, 2026IQVIA Holdings Inc.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalAgainstFor

Search this fund’s votes by company

487 ballot items at 64 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, AlphaCentric Life Sciences and Healthcare Fund (LYFAX) voted at 64 shareholder meetings of 61 companies, on 487 ballot items in all. Where management made a recommendation, the fund followed it on 98.6% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (6 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals less often than MUTUAL FUND SERIES TRUST's funds as a whole (82.6% against 93.0%). It voted differently from most MUTUAL FUND SERIES TRUST funds on 2 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of MUTUAL FUND SERIES TRUST’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.